
A dual GIP/GLP-1 receptor agonist that has demonstrated significant effects in metabolic and weight management research. One of the most extensively studied incretin-based compounds.
For Research Use Only. This product is not intended for human consumption. By purchasing, you confirm this product will be used for research purposes only.
99%+ Purity
HPLC Verified
Fast Shipping
2-3 Day Delivery
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that represents a breakthrough in metabolic research. As the first peptide to simultaneously target both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, it has opened new frontiers in metabolic regulation.
For research use only — not for human consumption.

A first-in-class triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied for its potential in metabolic research and body composition.

A dual GLP-1/glucagon receptor agonist combining appetite regulation with enhanced energy expenditure. Actively studied for metabolic and hepatic fat research.

An essential coenzyme involved in over 500 enzymatic reactions, serving as a substrate for sirtuins and PARPs. Central to aging, DNA repair, and metabolic function research.

A mitochondrial-derived peptide that activates the AMPK signaling pathway. Studied as a potential exercise mimetic with effects on glucose metabolism and insulin sensitivity.